Skip to Content

BeiGene Ltd Ordinary Shares 06160

Morningstar Rating
HKD 99.40 +6.60 (7.11%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

06160 is trading at a 689% premium.
Price
HKD 93.64
Fair Value
HKD 852.66
Uncertainty
High
1-Star Price
HKD 272.26
5-Star Price
HKD 81.23
Economic Moat
Wshrhs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 06160 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
HKD 92.80
Day Range
HKD 98.20100.20
52-Week Range
HKD 75.45139.90
Bid/Ask
HKD 99.20 / HKD 99.40
Market Cap
HKD 135.08 Bil
Volume/Avg
1.9 Mil / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.87
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene’s key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
10,000

Comparables

Valuation

Metric
06160
09939
09969
Price/Earnings (Normalized)
Price/Book Value
4.831.121.04
Price/Sales
5.8710.64
Price/Cash Flow
Price/Earnings
06160
09939
09969

Financial Strength

Metric
06160
09939
09969
Quick Ratio
1.732.074.10
Current Ratio
2.082.104.19
Interest Coverage
−110.66−31.46
Quick Ratio
06160
09939
09969

Profitability

Metric
06160
09939
09969
Return on Assets (Normalized)
−7.03%−64.88%−7.58%
Return on Equity (Normalized)
−10.84%−97.47%−10.64%
Return on Invested Capital (Normalized)
−10.66%−75.42%−11.54%
Return on Assets
06160
09939
09969
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
MtwbcmskNjmdgm$124.3 Bil
Regeneron Pharmaceuticals Inc
REGN
TrgpmftnqYhpckx$111.3 Bil
Moderna Inc
MRNA
DpgdnpxBkm$56.9 Bil
BioNTech SE ADR
BNTX
PbhbzydQlyg$24.2 Bil
argenx SE ADR
ARGX
CrtzysjmKhwg$22.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
DrcmpvvywBlvqgq$20.1 Bil
Biomarin Pharmaceutical Inc
BMRN
MmmbnlkJtcypz$16.1 Bil
Incyte Corp
INCY
GqpqqdwsKhcgdd$13.4 Bil
Royalty Pharma PLC Class A
RPRX
BqbhzqnvgSgfjq$12.4 Bil
United Therapeutics Corp
UTHR
TknbccjkCzpg$12.2 Bil

Sponsor Center